MarketInOut Stock Screener Log In | Sign Up

Crism Therapeutics Corp

LSE • Healthcare • Biotechnology • Quote as of 10/27/2026 15:09
Crism Therapeutics Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeLSE
Market Capitalization6.92 mln
Float53.32 mln
Earnings Date06/11/2027

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

5.24
Highly suspicious

Relative Strength

23 / 100
Significantly lagging

Pre-Tax Margin

-813%
Severely loss-making

ROE

-136
Deeply negative

Altman Z-Score

8.7
Exceptional

Business Description

CRISM Therapeutics Corporation is a medical company focused on improving how chemotherapy reaches solid tumors by delivering treatment directly into cancer tissue rather than through the bloodstream. Its primary product, ChemoSeed, is a small biodegradable implant placed directly at the tumor site, designed to release chemotherapy drugs locally and more effectively. The company also supports other organizations through drug formulation and advisory services. Founded in 2016 and headquartered in Road Town, British Virgin Islands, CRISM was previously known as Amur Minerals Corporation before adopting its current name in May 2024.

Key Fundamentals

EPS-5.00
ROE-136
RPS0.01
ROIC-308
ROA-107
EBITDA, mln-2.38
EV / EBITDA-3.46
EV / EBIT-3.43
Revenue, mln0.35
EV / Revenue27.88

Quote Details

Last 8.50
Change -0.17 (-1.96%)
Open 8.75
Volume 21,016
Turnover 178,636
Average Volume 45,851

Financial Ratios

Pre-Tax Profit Margin-813
Leverage Ratio1.13
Current Ratio4.35
Price / Book3.61
Price / Tangible Book3.25
Price / Sales16.25

Financial Strength

Altman Z-Score8.7
Piotroski F-Score 2 / 9
Beneish M-Score5.24
Shiller PE Ratio0.13

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0% 46 / 100   
1 Month -13.27% 7 / 100   
2 Months -5.56% 23 / 100   
6 Months -29.17% 7 / 100   
1 Year -15% 15 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog